ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2035-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to investigate whether adjuvant chemotherapy can prevent disease recurrence in patients with high-risk rectal cancer who have detectable ctDNA after surgery.
The main research question the REACT study aims to answer is:
\- Does adjuvant chemotherapy improve disease-free survival in patients with high-risk rectal cancer with detectable ctDNA after surgery?
Interventions:
\- Patients with detectable ctDNA after surgery and randomised to the experimental group will be offered adjuvant chemotherapy (4 cycles CAPOX/6 cycles FOLFOX) within 12 weeks after surgery.
Phase:
PHASE3
Details
Lead Sponsor:
Erasmus Medical Center
Collaborators:
Dutch Colorectal Cancer Group (DCCG) Prospectief Landelijk CRC Cohort (PLCRC)